NCT00032916 is a Phase 1 clinical trial of NS2359 in Cocaine-Related Disorders, sponsored by National Institute on Drug Abuse (NIDA).

Who is sponsoring NCT00032916?

NCT00032916 is sponsored by National Institute on Drug Abuse (NIDA).

What drugs are being tested in NCT00032916?

Interventions in NCT00032916: NS2359.

What condition does NCT00032916 study?

NCT00032916 studies Cocaine-Related Disorders, Drug Administration Schedule, Infusions, Intravenous.

Is NCT00032916 still recruiting?

NCT00032916 is currently status unknown. Last updated 10 January 2017.

Last reviewed 2017-01-10 · How we verify

NCT00032916

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Drug Interaction Study With NS2359 and Cocaine in Cocaine Experienced Volunteers

Status unknown Phase 1 Last updated 10 January 2017

What this trial tests

Phase 1 trial testing NS2359 in Cocaine-Related Disorders in 24 participants. Status unknown.

Timeline

1 June 2001

1 December 2002

Quick facts

Lead sponsor	National Institute on Drug Abuse (NIDA)
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Masking	double
Primary purpose	treatment
Enrollment	24
Start date	1 June 2001
Estimated completion	1 December 2002
Sites	1 location across United States

Drugs / interventions tested

NS2359 — full drug profile →

Conditions studied

Cocaine-Related Disorders — all drugs for Cocaine-Related Disorders →
Drug Administration Schedule — all drugs for Drug Administration Schedule →
Infusions, Intravenous — all drugs for Infusions, Intravenous →

Sponsor

National Institute on Drug Abuse (NIDA)

Who can join

Adults 18 to 45, any sex, with Cocaine-Related Disorders or Drug Administration Schedule. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacokinetic parameter comparison
plasma concentration

Sponsor's own description

The purpose of this study is to conduct a drug interaction study with NS2359 and cocaine in cocaine experienced volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other National Institute on Drug Abuse (NIDA) trials

Trials by the same sponsor.

NCT07468552 — Trial of Tirzepatide for the Treatment of Cannabis Use Disorder · Phase 2 · not yet recruiting
NCT06808932 — VK4-116 Phase I Study With Food-Effect · Phase 1 · not yet recruiting
NCT06676059 — SMART-r: Substance Monitoring and Active Relapse Tracking Repository · recruiting
NCT06577454 — Measuring the Effects of Neurostimulation on Risky and Ambiguous Decision-Making Capacity in People With and Without Sub · NA · suspended
NCT06868914 — Phase I Trial of High-Density Theta Burst Stimulation (hdTBS) · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00032916 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA)
Last refreshed: 10 January 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00032916.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing